Ren Yi-Jiu, She Yun-Lang, Dai Chen-Yang, Jiang Ge-Ning, Fei Ke, Chen Chang
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China
Interact Cardiovasc Thorac Surg. 2016 Mar;22(3):321-6. doi: 10.1093/icvts/ivv353. Epub 2015 Dec 24.
Although non-small-cell lung cancer (NSCLC) with malignant pleural nodules is generally contraindicated for surgery, there is no consensus concerning on-site operative decisions for unexpected, intraoperatively encountered malignant pleural disseminations. The rationale underlying the primary tumour removal and other aggressive interventions remains controversial.
All surgical NSCLC cases (9576) of Shanghai Pulmonary Hospital between January 2005 and December 2013 were reviewed. Among them, 83 cases (0.9%) met the definition of 'unexpected' macroscopic malignant pleural nodules, despite routine preoperative evaluations for tumour metastasis. No pleural effusion was visualized in 52 cases during operations, and 31 had pleural effusion in minimal volume (<300 ml). Survivals were calculated with the Kaplan-Meier method and risk factors were evaluated by the log-rank test.
The overall 3- and 5-year survival rates were 36.1 and 16.8%, respectively. The median survival time (MST) after surgery was significantly longer in the group without pleural effusion (37 months) compared with the group with pleural effusion (22 months, P = 0.005). Twenty-one cases had only biopsy, whereas 62 cases had primary tumour resection. Primary tumour resection had significantly better outcome compared with biopsy (MST: respectively, 35 vs 17 months, 3-year survival rate 45.8 vs 11.8%, P = 0.001). No baseline differences emerged in characteristics between biopsy and primary tumour resection groups including targeted therapy. Multivariate analysis showed that primary tumour resection (HR: 3.678, P = 0.014), no pleural effusion (HR: 3.409, P = 0.001) and adenocarcinoma (HR: 5.481, P = 0.002) were favourable prognostic factors in patients with malignant pleural nodules.
Patients with malignant pleural nodules but without pleural effusion had better survival compared with those with effusions. Primary tumour resection had survival benefits for patients with unexpected intraoperatively proven malignant pleural nodules.
尽管伴有恶性胸膜结节的非小细胞肺癌(NSCLC)通常禁忌手术,但对于术中意外发现的恶性胸膜播散的现场手术决策尚无共识。切除原发肿瘤及其他积极干预措施的理论依据仍存在争议。
回顾性分析上海肺科医院2005年1月至2013年12月期间所有手术治疗的NSCLC病例(9576例)。其中,83例(0.9%)尽管术前常规评估肿瘤转移情况,但仍符合“意外”肉眼可见恶性胸膜结节的定义。术中52例未见胸腔积液,31例胸腔积液量极少(<300 ml)。采用Kaplan-Meier法计算生存率,通过log-rank检验评估危险因素。
总体3年和5年生存率分别为36.1%和16.8%。无胸腔积液组术后中位生存时间(MST)(37个月)显著长于有胸腔积液组(22个月,P = 0.005)。21例行活检,62例行原发肿瘤切除。与活检相比,原发肿瘤切除的预后明显更好(MST:分别为35个月和17个月,3年生存率45.8%对11.8%,P = 0.001)。活检组和原发肿瘤切除组在包括靶向治疗在内的特征方面未发现基线差异。多因素分析显示,原发肿瘤切除(HR:3.678,P = 0.014)、无胸腔积液(HR:3.409,P = 0.001)和腺癌(HR:5.481,P = 0.002)是恶性胸膜结节患者的有利预后因素。
与有胸腔积液的患者相比,伴有恶性胸膜结节但无胸腔积液的患者生存率更高。对于术中证实为意外恶性胸膜结节的患者,切除原发肿瘤可带来生存获益。